Hypogammaglobulinemia
Hypogammaglobulinemia
Explore linked clinical trials. Standard reference: MESH:M00005526 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM | Blood Protein Disorders, DNA Virus Infections, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, agammaglobulinemia, common wart, hematologic disorder, human papilloma virus infection, immune system disorder, immunodeficiency disease, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome, skin disorder, skin disorder caused by infection, viral infectious disease | Enrolling by invitation | Phase 1 / Phase 2 | 2026-10-09 | NCT07775313 | |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired, Neoplasms by Histologic Type, agammaglobulinemia, cardiovascular disorder, common variable immunodeficiency, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-10-05 | NCT06976476 | |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | B-cell chronic lymphocytic leukemia, Bacterial Infections and Mycoses, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, agammaglobulinemia, bacterial infectious disease, hematologic disorder, immune system disorder, immunoproliferative disorder, inborn error of immunity, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 3 | 2026-09-30 | NCT05645107 | |
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, agammaglobulinemia, hematologic disorder, immune system disorder, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome | Recruiting | Phase 3 | 2026-09-29 | NCT07220915 | |
| Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? | Blood Protein Disorders, CNS demyelinating autoimmune disease, Fatigue, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agammaglobulinemia, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, hematologic disorder, immune system disorder, inborn error of immunity, lymphatic system disorder, lymphoproliferative syndrome, multiple sclerosis, nervous system disorder | Recruiting | Not stated | 2026-05-01 | NCT05357781 | |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypogammaglobulinemia, Infections, Neoplasms by Histologic Type, Neoplasms by Site, agammaglobulinemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, inborn error of immunity, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, plasma cell neoplasm | Recruiting | Phase 2 / Phase 3 | 2024-04-19 | NCT05678621 |